ClinicalTrials.gg
Not yet recruitingNCT07805382DREAMSUpdated Nov 16, 2026

Dynamic Relationships Between Estrogen Fluctuations, Sleep, and Psychiatric Complexity Among Adolescent Females With ADHD

An observational study in ADHD, sponsored by Duke University. Not yet recruiting at 1 site in United States. Open to female participants aged 11 Years to 15 Years. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by Duke University · Observational

Updated Nov 16, 2026Start date movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
30
Ages
11 Years to 15 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 19 studies in Attention Deficit Disorder with Hyperactivity by Duke University — 3 open to participants now, 3 under way, none of them phase 3. Attention Deficit Disorder with Hyperactivity · Duke University.

Started
2026
the only one that year
Observational
5 of 19
3 open now
Registered
19th of 19
by date

Among the 19 studies in Attention Deficit Disorder with Hyperactivity by Duke University, this one is the only one that started in 2026, is one of 5 observational ones, and was the 19th registered.

Attention Deficit Disorder with Hyperactivity

1,817 studies on the registry are indexed under Attention Deficit Disorder with Hyperactivity; 295 are open to participants now.

Browse Attention Deficit Disorder with Hyperactivity studies →

Open to participants now

3 of the 19 studies in Attention Deficit Disorder with Hyperactivity by Duke University are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 201 Attention Deficit Disorder with Hyperactivity studies recruiting now, 27 (13%) set no upper age limit and 169 (84%) stop at 75 or younger; 141 take children under 18; 55 take healthy volunteers.

This study: 11 Years to 15 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies in Attention Deficit Disorder with Hyperactivity by Duke University, or all of them as a file.
02

Study summary

The purpose of the study is to establish the feasibility of collecting estradiol (E2), Garmin-measured sleep, and ecological momentary assessments (EMA) of ADHD and related symptoms (mood, anxiety, executive functioning) across menstrual cycles among 20 peripubertal female adolescents aged 11-15 with ADHD, and to explore links between within-individual E2 variability, sleep, and EMA-derived outcomes.

Read the detailed description

The overall objective is to establish the feasibility of collecting estradiol (E2), Garmin-measured sleep, and ecological momentary assessments (EMA) of ADHD and related symptoms (mood, anxiety, executive functioning) among adolescent females with Attention Deficit Hyperactivity Disorder (ADHD) and explore the links between within-individual E2 variability and EMA-derived outcomes, across menstrual cycles in this population. We aim to establish sufficient pilot data to support a large-scale study focused on characterizing relationships between E2 across the menstrual cycle, sleep, ADHD symptoms, and related symptomatology in adolescent females with ADHD. Participants will complete an initial screening visit answering questionnaires related to puberty, ADHD, and sleep to establish eligibility. After completing a device training session, we will ask participants to provide daily urine E2 samples and EMA brief assessments of ADHD and related clinical features (i.e., mood, executive functioning, sleep) over 2 menstrual cycles (\~56 days). Sleep will be assessed continuously over the study period via convenient wearable (Garmin watch). Feasibility of protocol will be assessed as days of successful E2 data collection, EMA completion, and Garmin wear. Feasibility benchmark=80% actual/anticipated data collection. Multilevel modeling will explore the relationship between within-person changes in E2, ADHD symptoms and related clinical outcomes, and whether sleep strengthens (moderates) these relationships.

03

Conditions studied

04

Who can participate

Ages eligible
11 Years to 15 Years
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Female adolescents ages 11-15 with ADHD in the Duke University Health System

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Female;
  • Ages 11-15;
  • Within 2 years of first menstrual cycle (menarche);
  • Parent-reported ADHD diagnosis and T score ≥65 on Inattention and/or Hyperactivity/Impulsivity via Conners
  • Access to internet and smartphone device with capacity to download the intervention App (iOS and Android);

Exclusion criteria

Exclusion Criteria:

  • Reported psychotic or bipolar disorder, sleep apnea, or restless leg syndrome;
  • Current suicidality/self-harm;
  • Plans to initiate/change psychotropic or sleep medications during participation
05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
30 participants (estimated)
Patient registry
No

Groups and cohorts

  • Adolescent Females with Attention Deficit Hyperactivity Disorder (ADHD)

    Participants will complete an initial screening visit answering questionnaires related to puberty, ADHD, sleep, and psychiatric health to establish eligibility. After completing a device training session, participants will be asked to provide daily urine E2 samples and EMA brief assessments of ADHD and related clinical features (i.e., mood, executive functioning, sleep) over 2 menstrual cycles (\~56 days).

06

What researchers measure

Primary outcomes

  1. Feasibility of Collecting Estradiol (E2)

    The percentage of actual E2 data collected compared to anticipated E2 data collected

    Time frame: 56 Days

  2. Feasibility of Collecting Garmin Data

    The percentage of actual Garmin data collected compared to anticipated Garmin data collected

    Time frame: 56 Days

  3. Feasibility of Collecting Ecological Momentary Assessments (EMA)

    The percentage of actual EMA data collected compared to anticipated EMA data collected

    Time frame: 56 Days

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2026; primary completion for Aug 2027, 8 months later.

Of 85 non-industry observational studies under Attention Deficit Disorder with Hyperactivity, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 69. This study's planned 8 months is below that.

Counting every sponsor, half of 95 studies reached it within 35 months; a quarter within 20 and three quarters within 69.

Start moved once since we started tracking on Sep 25, 2026: Sep 2026 → Dec 2026, on Nov 16, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 27, 2026
First posted
Sep 4, 2026
StartEst.
Dec 2026was Sep 2026
Primary completionEst.
Aug 2027
CompletionEst.
Aug 2027
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Sep 2026→Dec 2026
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    Start date Sep 2026→Dec 2026

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07805382
Lead sponsor
Duke University
Responsible party
Sponsor
First posted
Sep 4, 2026
Start date
Dec 2026 (estimated)
Primary completion
Aug 2027 (estimated)
Completion
Aug 2027 (estimated)
Last update
Nov 16, 2026

Study contacts

Matthew Gibson
Contact
matthew.gibson646@duke.edu
9196812521
Jessica Lunsford-Avery, Ph.D.
principal investigator · Duke University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion